Boston Family Office LLC raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 1.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,630 shares of the company’s stock after buying an additional 750 shares during the period. Boston Family Office LLC’s holdings in Novo Nordisk A/S were worth $1,770,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in NVO. Synovus Financial Corp raised its stake in Novo Nordisk A/S by 41.5% in the third quarter. Synovus Financial Corp now owns 8,700 shares of the company’s stock valued at $360,000 after buying an additional 2,550 shares during the last quarter. Bradley Foster & Sargent Inc. CT raised its stake in Novo Nordisk A/S by 4.0% in the third quarter. Bradley Foster & Sargent Inc. CT now owns 40,759 shares of the company’s stock valued at $1,695,000 after buying an additional 1,570 shares during the last quarter. Dillon & Associates Inc. raised its stake in Novo Nordisk A/S by 0.6% in the third quarter. Dillon & Associates Inc. now owns 114,904 shares of the company’s stock valued at $4,826,000 after buying an additional 704 shares during the last quarter. Quantbot Technologies LP raised its stake in Novo Nordisk A/S by 4,488.4% in the third quarter. Quantbot Technologies LP now owns 232,496 shares of the company’s stock valued at $9,669,000 after buying an additional 227,429 shares during the last quarter. Finally, Willingdon Wealth Management raised its stake in Novo Nordisk A/S by 72.4% in the third quarter. Willingdon Wealth Management now owns 39,413 shares of the company’s stock valued at $1,639,000 after buying an additional 16,555 shares during the last quarter. Institutional investors and hedge funds own 6.38% of the company’s stock.

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S (NYSE NVO) traded up 1.43% during midday trading on Friday, reaching $43.20. 2,753,595 shares of the company’s stock traded hands. The stock’s 50 day moving average price is $41.60 and its 200-day moving average price is $36.77. Novo Nordisk A/S has a one year low of $30.89 and a one year high of $57.41. The stock has a market cap of $107.82 billion, a PE ratio of 18.86 and a beta of 0.67.

TRADEMARK VIOLATION NOTICE: “Boston Family Office LLC Increases Stake in Novo Nordisk A/S (NVO)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/06/16/boston-family-office-llc-raises-position-in-novo-nordisk-as-nvo-updated-updated-updated.html.

NVO has been the subject of several recent analyst reports. Zacks Investment Research lowered shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research note on Wednesday, April 19th. Barclays PLC began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, March 7th. They issued an “underweight” rating for the company. TheStreet raised shares of Novo Nordisk A/S from a “c+” rating to a “b-” rating in a report on Tuesday, May 2nd. HSBC Holdings plc downgraded shares of Novo Nordisk A/S from a “hold” rating to a “reduce” rating in a report on Friday, April 7th. Finally, BidaskClub raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $57.00.

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Receive News & Stock Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related stocks with our FREE daily email newsletter.